Mar 02, 2026

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

Feb 26, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026

Lantheus to Present at March 2026 Investor Conferences

Feb 12, 2026

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

Jan 02, 2026

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies